Paper Details
- Home
- Paper Details
Original Abstract of the Article :
Severe diarrhoea after chemotherapy is a dose-limiting toxicity of first-line chemotherapeutic agents approved for the treatment of colorectal cancer including 5-fluorouracil + leucovorin (5-FU/LV) and irinotecan (CPT-11). This report explores the potential of the long-acting version of the somatost...See full text at original site
Dr.Camel's Paper Summary Blogラクダ博士について
ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。
* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。
引用元：
https://pubmed.ncbi.nlm.nih.gov/15305907
データ提供：米国国立医学図書館（NLM）
Octreotide LAR: A Solution for Severe Chemotherapy-Induced Diarrhoea
This research explores the use of [Octreotide LAR, a long-acting somatostatin analogue] in [Managing severe chemotherapy-induced diarrhoea (CID)]. The study focuses on [Secondary prophylaxis] for [Patients with colorectal cancer] who experience [Refractory diarrhoea] following [Fluoropyrimidine or irinotecan therapy]. The researchers report [Successful resolution of diarrhoea and prevention of further episodes] in [Three patients] who received [Octreotide LAR]. These findings suggest [Octreotide LAR] as a potential [Therapeutic option] for [Severe CID].
Octreotide LAR: A Powerful Tool for CID Management
This research demonstrates the effectiveness of [Octreotide LAR] in [Resolving severe CID] and [Preventing further episodes] in [Patients with colorectal cancer]. The study found that [Octreotide LAR] significantly [Improved quality of life] for these patients, allowing them to [Complete their chemotherapy treatment] without [Further hospitalization]. This highlights the importance of [Considering Octreotide LAR] as a [Therapeutic option] for [Severe CID].
Navigating the Desert of Chemotherapy
Imagine a desert journey, where the traveler faces unexpected obstacles and hardships. This research is like a map, guiding oncologists through the [Challenges of chemotherapy-induced diarrhoea]. The study highlights the potential of [Octreotide LAR] to [Provide relief and enable patients to complete their treatment], offering hope and support in the face of adversity.
Dr.Camel's Conclusion
This research is like a desert oasis, offering a much-needed respite from the [Challenges of chemotherapy-induced diarrhoea]. The findings suggest that [Octreotide LAR] can be a powerful tool in [Managing severe CID], allowing patients to complete their treatment with greater comfort and quality of life. This research reminds us that even in the face of challenging medical conditions, there is always hope for a brighter future.
Date :
- Date Completed 2005-03-10
- Date Revised 2013-11-21
Related Literature
English
This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.